Skip to main
  1. Stocks
  2. Guardant Health Inc
  3. Forecast
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is fundamentally attractive because it combines market leadership in liquid biopsy with multiple growth engines in Guardant360, Reveal, and Shield, while its underpenetrated cancer-testing markets still offer meaningful room for adoption. Recent catalysts materially de-risk the story: Q1’26 revenue rose 48% year over year to $302 million, oncology test volumes increased 47%, and the company held $1.2 billion of cash, while UHC’s Shield coverage effective August 1, 2026 and ACS guideline inclusion should expand both volumes and reimbursement. With 2026 guidance lifted to $1.30-$1.32 billion and continued ASP upside from FDA approval, ADLT prospects, and broader payer coverage, the stock’s positive outlook is anchored in durable growth, improving margins, and a long runway for commercialization.

Bears say

Guardant Health is viewed negatively because its core Guardant360 franchise still represents more than 60% of sales, yet investors have already seen sensitivity to any growth deceleration and recent 30% year-over-year volume growth is unlikely to be sustained. The company also faces a tougher competitive backdrop in MRD and screening, where Reveal competes against more established tissue-informed approaches and Shield’s addressable market may be smaller than expected without clearer USPSTF support. Financially, Guardant has burned more than $200 million in cash in each of the past two years, burn accelerated in the most recent quarter, and any slippage from management’s Q4 2027 breakeven target could pressure the balance sheet.

GH has been analyzed by 24 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

GH Analyst Forecast & Price Prediction

Get the latest GH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 24 analysts, GH has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $190.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $190.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


GH Analyst Forecast & Price Prediction

Get the latest GH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GH stock data and trends